Press release
PI3K Inhibitor Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | OnKure Therapeutics, Eli Lilly, BeiGene, Relay Therapeutics, Rhizen Pharmaceuticals, Curis
"PI3K Inhibitor Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PI3K Inhibitor Market.
The PI3K Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the PI3K Inhibitor Pipeline Report:
*
Companies across the globe are diligently working toward developing novel PI3K Inhibitor treatment therapies with a considerable amount of success over the years.
*
PI3K Inhibitor companies working in the treatment market are OnKure Therapeutics, Eli Lilly, BeiGene, Relay Therapeutics, Rhizen Pharmaceuticals, Curis, Celcuity, ThromBio, Suzhou Teligene, and others, are developing therapies for the PI3K Inhibitor treatment
*
Emerging PI3K Inhibitor therapies in the different phases of clinical trials are- OKI 219, STX 478, BGB 10188, RLY 2608, Tenalisib, Fimepinostat, Gedatolisib, TBO-309, TL117, and others are expected to have a significant impact on the PI3K Inhibitor market in the coming years.
*
In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting April 5-10 in San Diego. BeiGene has nine abstracts scheduled for poster presentations at AACR. An additional clinical presentation includes the first data from a Phase Ia dose escalation study of BGB-10188, a phosphatidylinositol 3 kinase delta (PI3K) inhibitor, plus tislelizumab in patients with solid tumors.
*
In May 2024, The FDA had granted breakthrough therapy designation to inavolisib (GDC-0077) plus palbociclib (Ibrance) and fulvestrant (Faslodex) for the treatment of patients with hormone receptor-positive, HER2- negative locally advanced or metastatic breast cancer harboring a PIK3CA mutation following recurrence on or within 12 months of completing adjuvant endocrine therapy.
*
In December 2023, Genentech a member of the Roche Group announced positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR) metastatic breast cancer.
PI3K Inhibitor Overview
A PI3K inhibitor is a type of targeted cancer therapy that blocks the activity of phosphoinositide 3-kinases (PI3Ks), enzymes involved in cell growth, survival, and metabolism. The PI3K/AKT/mTOR pathway is often overactive in various cancers, leading to uncontrolled cell proliferation and resistance to cell death.
PI3K inhibitors are designed to interrupt this signaling pathway, thereby slowing down or stopping tumor growth. These inhibitors may target different PI3K isoforms (, , , ), with some therapies selectively inhibiting specific isoforms to reduce side effects.
PI3K inhibitors are approved or under investigation for cancers such as chronic lymphocytic leukemia (CLL), follicular lymphoma, and breast cancer. Examples include idelalisib, alpelisib, and duvelisib. Common side effects may include diarrhea, rash, liver toxicity, and immune suppression.
Get a Free Sample PDF Report to know more about PI3K Inhibitor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pi3k-inhibitor-pipeline-insight [https://www.delveinsight.com/report-store/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging PI3K Inhibitor Drugs Under Different Phases of Clinical Development Include:
*
OKI 219: OnKure Therapeutics
*
STX 478: Eli Lilly
*
BGB 10188: BeiGene
*
RLY 2608: Relay Therapeutics
*
Tenalisib: Rhizen Pharmaceuticals
*
Fimepinostat: Curis
*
Gedatolisib: Celcuity
*
TBO-309: ThromBio
*
TL117: Suzhou Teligene
PI3K Inhibitor Route of Administration
PI3K Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
PI3K Inhibitor Molecule Type
PI3K Inhibitor Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
PI3K Inhibitor Pipeline Therapeutics Assessment
*
PI3K Inhibitor Assessment by Product Type
*
PI3K Inhibitor By Stage and Product Type
*
PI3K Inhibitor Assessment by Route of Administration
*
PI3K Inhibitor By Stage and Route of Administration
*
PI3K Inhibitor Assessment by Molecule Type
*
PI3K Inhibitor by Stage and Molecule Type
DelveInsight's PI3K Inhibitor Report covers around 25+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further PI3K Inhibitor product details are provided in the report. Download the PI3K Inhibitor pipeline report to learn more about the emerging PI3K Inhibitor therapies [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the PI3K Inhibitor Therapeutics Market include:
Key companies developing therapies for PI3K Inhibitor are - Pfizer, Incyte Corporation, Yuhan, TG Therapeutics, Inflection Biosciences/AUM Biosciences, Onconova Therapeutics, UCB, and others.
PI3K Inhibitor Pipeline Analysis:
The PI3K Inhibitor pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of PI3K Inhibitor with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PI3K Inhibitor Treatment.
*
PI3K Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
PI3K Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PI3K Inhibitor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about PI3K Inhibitor drugs and therapies [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
PI3K Inhibitor Pipeline Market Drivers
*
Increasing Prevalence of Cancer, Increasing research on the effect of PI3K Inhibitors, are some of the important factors that are fueling the PI3K Inhibitor Market.
PI3K Inhibitor Pipeline Market Barriers
*
However, Increasing research on the effect of PI3K Inhibitors, Adverse effects associated with the PI3K inhibitors, and other factors are creating obstacles in the PI3K Inhibitor Market growth.
Scope of PI3K Inhibitor Pipeline Drug Insight
*
Coverage: Global
*
Key PI3K Inhibitor Companies: OnKure Therapeutics, Eli Lilly, BeiGene, Relay Therapeutics, Rhizen Pharmaceuticals, Curis, Celcuity, ThromBio, Suzhou Teligene, and others
*
Key PI3K Inhibitor Therapies: OKI 219, STX 478, BGB 10188, RLY 2608, Tenalisib, Fimepinostat, Gedatolisib, TBO-309, TL117, and others
*
PI3K Inhibitor Therapeutic Assessment: PI3K Inhibitor current marketed and PI3K Inhibitor emerging therapies
*
PI3K Inhibitor Market Dynamics: PI3K Inhibitor market drivers and PI3K Inhibitor market barriers
Request for Sample PDF Report for PI3K Inhibitor Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. PI3K Inhibitor Report Introduction
2. PI3K Inhibitor Executive Summary
3. PI3K Inhibitor Overview
4. PI3K Inhibitor- Analytical Perspective In-depth Commercial Assessment
5. PI3K Inhibitor Pipeline Therapeutics
6. PI3K Inhibitor Late Stage Products (Phase II/III)
7. PI3K Inhibitor Mid Stage Products (Phase II)
8. PI3K Inhibitor Early Stage Products (Phase I)
9. PI3K Inhibitor Preclinical Stage Products
10. PI3K Inhibitor Therapeutics Assessment
11. PI3K Inhibitor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. PI3K Inhibitor Key Companies
14. PI3K Inhibitor Key Products
15. PI3K Inhibitor Unmet Needs
16 . PI3K Inhibitor Market Drivers and Barriers
17. PI3K Inhibitor Future Perspectives and Conclusion
18. PI3K Inhibitor Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pi3k-inhibitor-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-onkure-therapeutics-eli-lilly-beigene-relay-therapeutics-rhizen-pharmaceuticals-curis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PI3K Inhibitor Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | OnKure Therapeutics, Eli Lilly, BeiGene, Relay Therapeutics, Rhizen Pharmaceuticals, Curis here
News-ID: 4099857 • Views: …
More Releases from ABNewswire
Total Joy Homecare Responds to Surging Demand for Senior Health Care Services in …
Total Joy Homecare expands services to meet growing Houston demand for in-home senior care, offering non-medical support that helps families maintain independence and dignity at home.
Houston's rapidly aging demographic has prompted local care provider Total Joy Homecare to expand its comprehensive support services, addressing the critical need for quality senior health care services [https://maps.app.goo.gl/hUcW1N7qWy5EdHJs5] throughout the Greater Houston area. The company's response comes as families increasingly seek reliable alternatives to…
Texas Company Introduces On-Site Carrier Repair Services to Reduce Fleet Downtim …
Texas Reefer Solutions introduces mobile carrier repair services in Dallas, revolutionizing how transportation fleets handle refrigeration breakdowns by providing on-site professional repairs, eliminating route deviations, and reducing cargo-threatening delays.
The transportation industry faces a significant challenge when refrigerated trucks require repairs, often forcing drivers to deviate from critical routes and schedules. Texas Reefer Solutions has emerged as a game-changing solution, introducing mobile carrier repair services [https://maps.app.goo.gl/P6nfg5WF7sckR7aZ8] that bring professional technicians directly…
Family Therapy in Birmingham: How the Right Therapist Can Transform Relationship …
Family therapy in Birmingham helps families improve communication, resolve conflict, and build stronger bonds. With the support of a qualified therapist near you, therapy creates a safe space to share, heal, and reconnect. Whether you're searching for therapy near me or counselling for your family, Phinity Therapy offers guidance for lasting change.
Families are the foundation of our lives. They provide love, support, and connection, but they can also be the…
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for PI3K
PI3K Inhibitors Market Outlook: Roche, Novartis, and Emerging Biotechs Drive Com …
DelveInsight's comprehensive analysis reveals robust growth potential in the PI3K inhibitors market across 7MM through 2034. Key players include Roche/Genentech (ITOVEBI), Novartis (PIQRAY), Gilead Sciences (ZYDELIG), Kazia Therapeutics (Paxalisib), Celcuity (Gedatolisib), and others, with expanding applications from hematological to solid tumor indications driving market momentum.
PI3K Inhibitor Key Takeaways
*
PI3K Inhibitor market size projection: As per DelveInsight's analysis, the total market size of PI3K inhibitors in the 7MM is expected to…
PI3K Inhibitors Market Projected to Witness Massive Growth - Novartis, Gilead Sc …
PI3K Inhibitors Market Snapshot
The PI3K Inhibitors Market is projected to reach USD 2.5 billion by 2032, growing at a CAGR of 8.2% from 2025 to 2032.
Coherent Market Insights proudly presents its latest PI3K Inhibitors Market Research Report, delivering a detailed examination of the U.S. PI3K Inhibitors Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels, addressing evolving supply networks, payer-provider collaboration,…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
PI3K inhibitors Pipeline Insights, Clinical Trials, Emerging Therapies and Compa …
DelveInsight's, "PI3K inhibitors Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the PI3K…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation Analysis and Glo …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Exclusive insight on Transfor …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
